Selected Alumni Stories

Many successful UZH and ETH spin-offs began their journey with the BEI program, leveraging our support to take their innovations to the next level. We’re proud to highlight the diverse paths of two standout ventures:  Eracal Therapeutics , which outlicensed its preclinical module to a major pharmaceutical company, and MUVON Therapeutics, which advanced its innovation to clinical trials after joining the Wyss Zurich accelerator.